医药行业近期动态：多项临床试验与产品上市进展

Group 1 - GSK and Ionis have achieved the primary endpoint in the Phase 3 clinical trial of Bepirovirsen for chronic hepatitis B, with plans to submit regulatory filings in Q1 2026 [1] - Merck's subcutaneous formulation of Pembrolizumab has received FDA approval for 2025, with a focus on transitioning patients from intravenous infusion to the new formulation in 2026 [1] - Guangsheng Pharmaceutical's innovative drug GST-HG141 has completed patient enrollment for Phase 3 clinical trials, while Alvotech and Teva's biosimilar Eylea (AVT06) is expected to launch in the U.S. in Q4 2026 [1]